Research Antibodies Market Worth $5.6 Billion By 2027
By: Gaurav Shah
Tags: Britain, Biotechnology, Research, Australia, China

The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018–2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Launch of novel antibody structures for diagnosis of various diseases is also a major factor expected to boost the market. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry. The company’s immunohistochemistry solution offers about 400 reagents, primary antibodies, consumables, and ancillaries. Key players in the market include Abcam Plc; Bio-Rad Laboratories Inc.; PerkinElmer, Inc.; Agilent Technologies; Roche; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; Lonza Group; and BD.

Click the link below:

https://www.grandviewresearch.com/industry-analysis/research-antibodies-market

Further key findings from the study suggest: